Treatments for HR+, HER2-Negative Metastatic Breast Cancer
New and emerging agents in HER2-negative metastatic breast cancer: Implications for practice
Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer
Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer
Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies
Important considerations in the management of HR+, HER2-negative early breast cancer
Treatment Options for HER2-Negative Breast Cancer
An Overview of the MERIBEL Study in HER2-Negative Breast Cancer
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast Cancer
Considering Treatment for HER2-Negative Breast Cancer
Case Study: Treating HR-Positive and HER2-Negative Breast Cancer
Management of premenopausal HR+/HER2- breast cancer with micro-metastasis
Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer
Myriad's BRACAnalysisCDx for Patients with HER2-Negative Metastatic Breast Cancer
Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer
PI3K inhibitors for the treatment of brain metastases in HER2-negative breast cancer
What Treatments Are Available for HER2-Positive Metastatic Breast Cancer?
Findings indicate HER2-low and HER2-negative breast cancer are biology indistinct
Comparing therapy benefit from initially HER2 positive or negative metastatic breast cancer patients
